Spleen and Bruton's tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials [0.03%]
成人自身免疫性血小板减少症管理中的脾切除术和泰他西普：随机对照试验的系统评价和meta分析
Akhil D Vatvani,Timotius I Hariyanto,Alejandrina C Ramirez et al.
Akhil D Vatvani et al.
Spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK) inhibitors have emerged as promising targeted therapies for adult immune thrombocytopenia (ITP). However, a comprehensive synthesis of their benefits compared to placebo has no...
Clonal hematopoiesis at the crossroads of Inflammaging and cardiovascular disease: Mechanistic insights and translational horizons [0.03%]
克隆性血细胞增多症位于炎症衰老和心血管疾病交叉路口：机制见解与转化前景
Soumiya Nadar,Taha K Dohadwala,Nitish Kumaresan et al.
Soumiya Nadar et al.
Clonal Hematopoiesis of indeterminate potential (CHIP) has been increasingly recognised as a risk factor for cardiovascular disease (CVD). Recent epidemiological and experimental studies have linked CHIP as an independent risk factor for my...
Ramadan fasting and hematological disorders: clinical considerations, risks, and management strategies [0.03%]
斋月封斋与血液系统紊乱：临床考虑、风险及管理策略
Abdulrahman Nasiri,Ahmed Alahmadi,Manal Alshammari et al.
Abdulrahman Nasiri et al.
Ramadan fasting induces significant physiological adaptations that can affect patients with hematological disorders. While fasting is generally safe for healthy individuals, reduced hydration and nutritional intake during the 13-18 hour fas...
Skills, attitude and knowledge for early-career hematologists: a pragmatic, scientific framework [0.03%]
实用主义科学框架下的青年血液科医师的职业技能、职业态度和职业知识调查
Mohamad Mohty,Yishan Ye,Rahul Banerjee
Mohamad Mohty
Erdheim-Chester Disease in Adults: 11 Cases from a Canadian Rare Diseases Program [0.03%]
成人 Erdheim-Chester 病的临床特征和治疗反应：加拿大罕见病项目的 11 例报告
Stephanie Quon,Emily Leung,Mark Trinder et al.
Stephanie Quon et al.
Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm with highly variable, multisystem manifestations that present significant diagnostic and therapeutic challenges. This retrospective multicenter case series included 11 adult patie...
Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis [0.03%]
发展中国家多发性骨髓瘤的治疗结果：系统评价和 meta 分析
Jehad Almasri,Bashar Hasan,Zin Tarakji et al.
Jehad Almasri et al.
Multiple myeloma (MM) treatment outcomes in developing countries may be impacted by resource constraints. This systematic review and meta-analysis evaluated efficacy outcomes of MM treatments across developing regions. Comprehensive searche...
DAIR to Be Different: Successful Use of DAIR Regimen, a Novel Treatment Combination for EBV-induced HLH [0.03%]
不一样的DAIR：EB病毒所致噬血细胞综合征使用DAIR方案新型治疗组合的病例报告
Adam Bouhadana,Amir Steinberg
Adam Bouhadana
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome caused by uncontrolled immune activation and hemophagocytosis. In adults, Epstein-Barr virus (EBV) infection is a known trigger. This report describes...
Networking for a successful career in clinical hematology: a strategic approach [0.03%]
临床血液学成功职业的战略式发展：打造良好的人际关系
Mohamad Mohty,Rahul Banerjee
Mohamad Mohty
Networking is fundamental to career development in clinical hematology, providing avenues for knowledge exchange, collaborations, and professional growth. This manuscript examines specific strategies for networking within this specialized f...
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study [0.03%]
来自EMMY研究的关于改善多发性骨髓瘤晚期患者护理的见解及现实世界的挑战
Titouan Cazaubiel,Olivier Decaux,Bruno Royer et al.
Titouan Cazaubiel et al.
Managing multiple myeloma (MM) patients receiving advanced (four or more) lines of treatment is a complex challenge. Therefore, real-world data are essential to better understand and address the medical need of this challenging population. ...
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group [0.03%]
复发难治多发性骨髓瘤抗CD38抗体类药物临床应用中国专家共识及推荐意见：泛太平洋多发性骨髓瘤工作组发起
Wenming Chen,Zhen Cai,Chor Sang Chim et al.
Wenming Chen et al.
Anti-CD38 monoclonal antibodies (mAbs), including daratumumab and isatuximab, have become key components of treatment for relapsed/refractory multiple myeloma (RRMM). This expert consensus provides evidence-based guidance on their optimal u...